Plasma Hyaluronic Acid level as a Prognostic and Monitoring Marker of Metastatic Breast Cancer

Cike Peng; Markus Wallwiener; Anja Rudolph; Katarina Ćuk; Ursula Eilber; Muhabbet Celik; Caroline Modugno; Andreas Trumpp; Jörg Heil; Frederik Marmé; Dharanija Madhavan; Juliane Nees; Sabine Riethdorf; Sarah Schott; Christof Sohn; Klaus Pantel; Andreas Schneeweiss; Jenny Chang-Claude; Rongxi Yang; Barbara Burwinkel

doi:10.1002/ijc.29975

Plasma Hyaluronic Acid level as a Prognostic and Monitoring Marker of Metastatic Breast Cancer

Standard

Plasma Hyaluronic Acid level as a Prognostic and Monitoring Marker of Metastatic Breast Cancer. / Peng, Cike; Wallwiener, Markus; Rudolph, Anja; Ćuk, Katarina; Eilber, Ursula; Celik, Muhabbet; Modugno, Caroline; Trumpp, Andreas; Heil, Jörg; Marmé, Frederik; Madhavan, Dharanija; Nees, Juliane; Riethdorf, Sabine; Schott, Sarah; Sohn, Christof; Pantel, Klaus; Schneeweiss, Andreas; Chang-Claude, Jenny; Yang, Rongxi; Burwinkel, Barbara.

in: INT J CANCER, Jahrgang 138, Nr. 10, 15.05.2016, S. 2499-509.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Peng, C, Wallwiener, M, Rudolph, A, Ćuk, K, Eilber, U, Celik, M, Modugno, C, Trumpp, A, Heil, J, Marmé, F, Madhavan, D, Nees, J, Riethdorf, S, Schott, S, Sohn, C, Pantel, K, Schneeweiss, A, Chang-Claude, J, Yang, R & Burwinkel, B 2016, 'Plasma Hyaluronic Acid level as a Prognostic and Monitoring Marker of Metastatic Breast Cancer', INT J CANCER, Jg. 138, Nr. 10, S. 2499-509. https://doi.org/10.1002/ijc.29975

APA

Peng, C., Wallwiener, M., Rudolph, A., Ćuk, K., Eilber, U., Celik, M., Modugno, C., Trumpp, A., Heil, J., Marmé, F., Madhavan, D., Nees, J., Riethdorf, S., Schott, S., Sohn, C., Pantel, K., Schneeweiss, A., Chang-Claude, J., Yang, R., & Burwinkel, B. (2016). Plasma Hyaluronic Acid level as a Prognostic and Monitoring Marker of Metastatic Breast Cancer. INT J CANCER, 138(10), 2499-509. https://doi.org/10.1002/ijc.29975

Vancouver

Peng C, Wallwiener M, Rudolph A, Ćuk K, Eilber U, Celik M et al. Plasma Hyaluronic Acid level as a Prognostic and Monitoring Marker of Metastatic Breast Cancer. INT J CANCER. 2016 Mai 15;138(10):2499-509. https://doi.org/10.1002/ijc.29975

Bibtex

@article{ad1a2f50d95d4a7ca1c576ae3bd30f06,

title = "Plasma Hyaluronic Acid level as a Prognostic and Monitoring Marker of Metastatic Breast Cancer",

abstract = "Conventional tumor markers have limited value for prognostication and treatment monitoring in metastatic breast cancer (MBC) patients and novel circulating tumor markers therefore need to be explored. Hyaluronic acid (HA) is a major macropolysaccharide in the extracellular matrix and is reported to be associated with tumor progression. In our study, we investigated plasma HA level with respect to progression free survival (PFS) and overall survival (OS), as well as the treatment monitoring value in MBC patients. The prognostic value of plasma HA level was investigated in a discovery cohort of 212 MBC patients with 2.5-year follow-up and validated in an independent validation cohort of 334 patients with 5-year follow-up. The treatment monitoring value of plasma HA level was investigated in 61 MBC patients from discovery cohort who had been radiographically examined after 1(st) complete cycle of chemo therapy. We found a robust association between high plasma HA level and poor prognosis of MBC patients in both discovery (pPFS = 7.92 × 10(-6) and pOS = 5.27 × 10(-5) ) and validation studies (pPFS = 3.66 × 10(-4) andpOS = 1.43 × 10(-4) ). In the discovery cohort, the plasma HA level displayed independent prognostic value after adjusted for age and clinicopathological factors, with respect to PFS and OS. Further, the decrease of plasma HA level displayed good concordance with treatment response evaluated by radiographic examination (AUC=0.79). Plasma HA level displays prognostic value, as well as treatment monitoring value for MBC patients. This article is protected by copyright. All rights reserved.",

author = "Cike Peng and Markus Wallwiener and Anja Rudolph and Katarina {\'C}uk and Ursula Eilber and Muhabbet Celik and Caroline Modugno and Andreas Trumpp and J{\"o}rg Heil and Frederik Marm{\'e} and Dharanija Madhavan and Juliane Nees and Sabine Riethdorf and Sarah Schott and Christof Sohn and Klaus Pantel and Andreas Schneeweiss and Jenny Chang-Claude and Rongxi Yang and Barbara Burwinkel",

note = "{\textcopyright} 2015 UICC.",

year = "2016",

month = may,

day = "15",

doi = "10.1002/ijc.29975",

language = "English",

volume = "138",

pages = "2499--509",

journal = "INT J CANCER",

issn = "0020-7136",

publisher = "Wiley-Liss Inc.",

number = "10",

}

RIS

TY - JOUR

T1 - Plasma Hyaluronic Acid level as a Prognostic and Monitoring Marker of Metastatic Breast Cancer

AU - Peng, Cike

AU - Wallwiener, Markus

AU - Rudolph, Anja

AU - Ćuk, Katarina

AU - Eilber, Ursula

AU - Celik, Muhabbet

AU - Modugno, Caroline

AU - Trumpp, Andreas

AU - Heil, Jörg

AU - Marmé, Frederik

AU - Madhavan, Dharanija

AU - Nees, Juliane

AU - Riethdorf, Sabine

AU - Schott, Sarah

AU - Sohn, Christof

AU - Pantel, Klaus

AU - Schneeweiss, Andreas

AU - Chang-Claude, Jenny

AU - Yang, Rongxi

AU - Burwinkel, Barbara

PY - 2016/5/15

Y1 - 2016/5/15

N2 - Conventional tumor markers have limited value for prognostication and treatment monitoring in metastatic breast cancer (MBC) patients and novel circulating tumor markers therefore need to be explored. Hyaluronic acid (HA) is a major macropolysaccharide in the extracellular matrix and is reported to be associated with tumor progression. In our study, we investigated plasma HA level with respect to progression free survival (PFS) and overall survival (OS), as well as the treatment monitoring value in MBC patients. The prognostic value of plasma HA level was investigated in a discovery cohort of 212 MBC patients with 2.5-year follow-up and validated in an independent validation cohort of 334 patients with 5-year follow-up. The treatment monitoring value of plasma HA level was investigated in 61 MBC patients from discovery cohort who had been radiographically examined after 1(st) complete cycle of chemo therapy. We found a robust association between high plasma HA level and poor prognosis of MBC patients in both discovery (pPFS = 7.92 × 10(-6) and pOS = 5.27 × 10(-5) ) and validation studies (pPFS = 3.66 × 10(-4) andpOS = 1.43 × 10(-4) ). In the discovery cohort, the plasma HA level displayed independent prognostic value after adjusted for age and clinicopathological factors, with respect to PFS and OS. Further, the decrease of plasma HA level displayed good concordance with treatment response evaluated by radiographic examination (AUC=0.79). Plasma HA level displays prognostic value, as well as treatment monitoring value for MBC patients. This article is protected by copyright. All rights reserved.

AB - Conventional tumor markers have limited value for prognostication and treatment monitoring in metastatic breast cancer (MBC) patients and novel circulating tumor markers therefore need to be explored. Hyaluronic acid (HA) is a major macropolysaccharide in the extracellular matrix and is reported to be associated with tumor progression. In our study, we investigated plasma HA level with respect to progression free survival (PFS) and overall survival (OS), as well as the treatment monitoring value in MBC patients. The prognostic value of plasma HA level was investigated in a discovery cohort of 212 MBC patients with 2.5-year follow-up and validated in an independent validation cohort of 334 patients with 5-year follow-up. The treatment monitoring value of plasma HA level was investigated in 61 MBC patients from discovery cohort who had been radiographically examined after 1(st) complete cycle of chemo therapy. We found a robust association between high plasma HA level and poor prognosis of MBC patients in both discovery (pPFS = 7.92 × 10(-6) and pOS = 5.27 × 10(-5) ) and validation studies (pPFS = 3.66 × 10(-4) andpOS = 1.43 × 10(-4) ). In the discovery cohort, the plasma HA level displayed independent prognostic value after adjusted for age and clinicopathological factors, with respect to PFS and OS. Further, the decrease of plasma HA level displayed good concordance with treatment response evaluated by radiographic examination (AUC=0.79). Plasma HA level displays prognostic value, as well as treatment monitoring value for MBC patients. This article is protected by copyright. All rights reserved.

U2 - 10.1002/ijc.29975

DO - 10.1002/ijc.29975

M3 - SCORING: Journal article

C2 - 26686298

VL - 138

SP - 2499

EP - 2509

JO - INT J CANCER

JF - INT J CANCER

SN - 0020-7136

IS - 10

ER -